Alan B Weiner

US Patent:

46108688, Sep 9, 1986

Filed:

Mar 20, 1984

Appl. No.:

6/591576

Inventors:

Michael W. Fountain - Plainsboro NJ
Steven J. Weiss - Lawrenceville NJ
John J. Kearns - Princeton NJ
Alan L. Weiner - Plainsboro NJ
Mircea C. Popescu - Plainsboro NJ

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 4300
A61K 4900

US Classification:

424 11

Abstract:

Lipid matrix carriers are described which provide for the sustained release of bioactive agents in vivo or in vitro. The properties of the lipid matrix carriers of the present invention include high entrapment efficiencies; release of entrapped compounds in their active form; biodegradability and avoidance of vascular occlusion in vivo; and avoidance of sequestration of the bioactive agent in the liver and spleen.

US Patent:

54662338, Nov 14, 1995

Filed:

Apr 25, 1994

Appl. No.:

8/232895

Inventors:

Alan L. Weiner - Cranbury NJ
Kevin Sinnett - Mukwonago WI
Sterling Johnson - Skillman NJ

Assignee:

Escalon Ophthalmics, Inc. - Skillman NJ

International Classification:

A61M 3500

US Classification:

6048901

Abstract:

A tack for intraocular drug delivery and a method for insertion and removal of an intraocular device for sustained release of a drug are provided. The tack comprises a post, an anchoring region and a head. The post is for being positioned within the vitreous region of the eye. The post has a first end and a second end, and includes a drug to be administered. The anchoring region is affixed to the second end of the post, and includes a width measured perpendicularly to a longitudinal axis of the tack which varies to provide the anchoring region with a configuration to anchor the tack within at least one of a sclera, a retina and a choroid. The head extends radially outwardly from the anchoring region such that upon insertion of the anchoring region and post within the eye, the head remains external to the eye and abuts a scleral surface of the eye. Other embodiments include a tack comprising a post, a central portion, a head and a suture hole through the head for anchoring the head to the sclera. Alternatively the tack comprises a post having a first portion of liquid drug, a hollow central portion filled with a second portion of liquid drug in fluid communication with the post and a head with an opening which allows for injection of subsequent doses of liquid drug through the head into the central portion.

US Patent:

59165880, Jun 29, 1999

Filed:

May 25, 1995

Appl. No.:

8/452549

Inventors:

Mircea C. Popescu - Plainsboro NJ
Alan L. Weiner - Lawrenceville NJ
Marie S. Recine - Hamilton Township NJ
Andrew S. Janoff - Yardley PA
Leonard Estis - Upton MA
Lynn D. Keyes - Upton MA
Carl R. Alving - Bethesda MD

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 9127
A61K 3900

US Classification:

424450

Abstract:

A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with the liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use. Immunizing dosage forms comprising a liposome and an immunogen, wherein the liposome and immunogen are present in an immunization dose. Additionally, a dosage form, including such form particularly adapted to producing an immune response, comprising a salt according to an organic acid derivative of a sterol and an immunogen are present in an immunization dose, and method according to uses is disclosed. Further, a dosage form, including such form particularly adapted to producing an immune response, comprising dimyristolyphosphatidylcholine (DMPC)/cholesterol liposomes, optionally in an aluminum hydroxide gel, and an immunogen wherein the DMPC/cholesterol and immunogen are present in an immunization dose, and method according to use.

US Patent:

47088613, Nov 24, 1987

Filed:

Jan 31, 1985

Appl. No.:

6/695887

Inventors:

Mircea C. Popescu - Plainsboro NJ
Alan L. Weiner - Plainsboro NJ

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 4300
A61K 4900

US Classification:

424 11

Abstract:

Compositions and methods for maintaining reservoirs of bioactive agents by sequestering the reservoir in a gel matrix are described. In particular, liposomes containing an entrapped bioactive agent are sequestered in a gel matrix. The resulting liposome-gel compositions may be used in vivo or in vitro to provide for sustained release of the bioactive agent. The gel matrix inhibits the dispersion and clearance of the sequestered liposomes without interfering with the ability of the liposomes to release the entrapped bioactive agent. Furthermore, the rate of release of the bioactive agent from the liposome-gel compositions may be varied by altering the composition of the liposomes and/or gels.

US Patent:

53669584, Nov 22, 1994

Filed:

Aug 20, 1993

Appl. No.:

8/110193

Inventors:

Alan L. Weiner - Plainsboro NJ
Robert P. Lenk - Lambertville NJ
Michael W. Fountain - Plainsboro NJ

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 3702
A61K 9127
A61K 9133
C07K 702

US Classification:

514 2

Abstract:

This invention encompasses new and substantially improved methods and compositions for delivery of therapeutic agents to specifically chosen body sites. Conjugation of fibronectin to bioactive agents or to lipids or to liposomes which entrap the bioactive agents permits immobilization of the bioactive agent when administered at collagen-, heparin-, hyaluronic acid-, fibrin/fibrinogen-, or ganglioside-rich sites. Covalent conjugation is achieved by two methods: (1) the enzymatically catalyzed cross-linkage of fibronectin to an amine containing compound, and (2) by a modified NHS method which permits formation of peptide bonds between fibronectin and lipid compounds.

US Patent:

60904062, Jul 18, 2000

Filed:

Feb 26, 1990

Appl. No.:

7/485388

Inventors:

Mircea C. Popescu - Plainsboro NJ
Alan L. Weiner - Lawrenceville NJ
Marie S. Recine - Hamilton Township NJ
Andrew S. Janoff - Yardley PA
Leonard Estis - Upton MA
Lynn D. Keyes - Upton MA
Carl R. Alving - Bethesda MD

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 9127
A61K 39385
A61K 3912
B01J 1302

US Classification:

424450

Abstract:

A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use. Immunizing dosage forms comprising a liposome and an immunogen, wherein said liposome and immunogen are present in an immunization dose. Additionally, a dosage form, including such form particularly adapted to producing an immune response, comprising a salt according to an organic acid derivative of a sterol and an immunogen wherein said organic acid derivative of a sterol and immunogen are present in an immunization dose, and method according to use is disclosed. Further, a dosage form, including such form particularly adapted to producing an immune response, comprising dimyristoylphosphatidylcholine (DMPC)/cholesterol liposomes, optionally in an aluminum hydroxide gel, and an immunogen wherein said DMPC/cholesterol and immunogen are present in an immunization dose, and method according to use.

US Patent:

51549301, Oct 13, 1992

Filed:

Feb 25, 1988

Appl. No.:

7/160141

Inventors:

Mircea C. Popescu - Plainsboro NJ
Paul A. Tremblay - Hamilton NJ
Andrew S. Janoff - Yardley PA
Marc J. Ostro - Princeton NJ
Elaine Chan - Willow Grove PA
Alan Weiner - Lawrenceville NJ

Assignee:

The Liposome Company, Inc. - Princeton NJ

International Classification:

A61K 914
A61K 948
A61K 966
A61K 31685

US Classification:

424489

Abstract:

A pharmacological agent-lipid solution preparation comprising a lipophilic pharmacological agent, a desalted charged lipid and an aqueous-miscible lipid solvent such that upon introduction into an aqueous medium a suspension of lipid aggregates associated with the pharmacological agent are formed, and methods of manufacture and use.